



Press Release

OncoMethylome Sciences and EXACT Sciences Announce Commercial Agreements for Colorectal Cancer Screening

Liege (Belgium) and Marlborough, MA (USA) – June 12, 2007, 8:00am CET – OncoMethylome Sciences (Euronext: ONCO) and EXACT Sciences Corporation (Nasdaq: EXAS) announced today that the companies have entered into agreements to advance the commercialization of stool-based colorectal cancer (CRC) screening technologies through service laboratories in Europe and North America.

Under the terms of a license agreement, EXACT has granted non-exclusive rights to its DNA stabilization, isolation and extraction technology to OncoMethylome for commercializing stool-based CRC screening tests in Europe that utilize OncoMethylome's methylation detection technology (Methylation-Specific PCR, or MSP). In exchange, OncoMethylome has agreed to pay royalties to EXACT based on sales.

Separately, the companies entered into a supply agreement in which OncoMethylome will sell reagents to EXACT for use in stool-based CRC screening services that EXACT may provide in North America. The reagents will enable EXACT to detect methylation at certain DNA markers using MSP technology. In addition, under the terms of this agreement, OncoMethylome also agreed to sell reagents to EXACT's commercial partners, subject to their negotiation with OncoMethylome of certain financial terms and other elements. Further financial details of the license and supply agreements were not disclosed.

The detection of methylated DNA is a key component of EXACT Sciences' Version 2 technology, which demonstrated 88 percent sensitivity for detecting colorectal cancer in a clinical study. The results of this study were published in the journal *Clinical Gastroenterology and Hepatology* in January, 2007.

"By combining our respective technologies, we have seen a significant improvement in the sensitivity of stool-based colorectal cancer screening," stated Herman Spolders, CEO of OncoMethylome Sciences. "These agreements provide a framework for commercializing this sensitive and non-invasive colorectal cancer screening technology in the U.S. and Europe."

Colorectal cancer mortality is a global problem. Worldwide there are more than 900,000 new cases diagnosed annually and with 500,000 deaths colorectal cancer is the second most deadly cancer. In Europe, there are 120 million people over the age of 50 who should be screened for colorectal cancer and it is estimated that a third of CRC-related deaths could be prevented if more people underwent regular screening.

"Improving colorectal cancer detection has always been the priority for EXACT Sciences," said Don Hardison, President and CEO of EXACT Sciences. "These agreements with OncoMethylome provide the companies with access to essential technologies that further this mission and enable us to advance the best, non-invasive screening option in the battle against colon cancer."

About OncoMethylome Sciences

OncoMethylome Sciences (Euronext Brussels: ONCOB; Euronext Amsterdam: ONCOA) is a molecular diagnostics company developing patent-protected gene methylation tests to assist physicians in effectively detecting and treating cancer. Specifically, the company's tests are designed to help the physician (i) accurately detect cancer in early stages of cancer development, (ii) predict a patient's response to drug therapy, and (iii) predict the likelihood of cancer recurrence.

OncoMethylome boasts a broad product development pipeline consisting of ten products and a solid partnering record. The company collaborates with leading international molecular oncology research centers, such as The Johns Hopkins University, and has a number of commercial and collaborative partnerships with Veridex LLC, a Johnson & Johnson company, Schering-Plough Corp., Chemicon International Inc., and EXACT Sciences Corp. OncoMethylome's products are based on methylation technology invented by Johns Hopkins University (USA).

Established in January 2003, OncoMethylome has offices in Liege and Leuven (Belgium), in Durham, NC (USA), and in Amsterdam (the Netherlands).

About EXACT Sciences Corporation

EXACT Sciences Corporation uses applied genomics to develop effective, patient-friendly screening technologies for use in the detection of cancer. Certain of its technologies have been licensed to Laboratory Corporation of America Holdings® (LabCorp®) for a stool-based DNA screening assay for colorectal cancer in the average-risk population. Colorectal cancer, which is the most deadly cancer among non-smokers, is generally curable if detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than 20 years, the rate of early detection of colorectal cancer remains low, and deaths from colorectal cancer remain high. EXACT Sciences believes its genomics-based technologies will help enable detection of colorectal cancer so that more people can be effectively treated. Founded in 1995, EXACT Sciences is based in Marlborough, Mass. PreGen-Plus(TM) has not been approved or cleared by the Food & Drug Administration.

For more information please contact:

OncoMethylome Sciences: Lucija Turcinov Tel. +32-479-801-902 Lucija.Turcinov@oncomethylome.com or visit: www.oncomethylome.com	EXACT Sciences: Jeff Luber Tel. +1-508-683-1200 jluber@exactsciences.com or visit www.exactsciences.com
---	---

EXACT Sciences Statement: Certain statements made in this press release that are not based on historical information are express or implied forward-looking statements relating to, among other things, EXACT Sciences' expectations concerning, among other things, the ability of EXACT Sciences to realize the expected benefits of its agreement with OncoMethylome, the efficacy of its colorectal cancer screening technology and management's plans, objectives and strategies. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond EXACT Sciences' control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things, the clinical performance and market acceptance of its technologies; the reproducibility of its research results in subsequent studies and in clinical practice; the inclusion of fecal DNA screening in colorectal cancer screening guidelines; sufficient investment in the sales and marketing of EXACT Sciences' technologies; the success of its strategic relationship with LabCorp; EXACT Sciences' ability to license certain technologies or obtain raw materials for its technologies; the ability to convince Medicare and other third-party payors to provide adequate reimbursement for EXACT Sciences' technologies; the ability to convince medical practitioners to order tests using EXACT Sciences' technologies; the ability of LabCorp to increase the performance of the PreGen-Plus test; the ability of EXACT Sciences or LabCorp to lower the cost stool-based DNA testing and of the PreGen-Plus test through automating and simplifying key

operational processes; the number of people who decide to be screened for colorectal cancer using EXACT Sciences' technologies; competition; the ability to protect EXACT Sciences' intellectual property and the cost of enforcing or defending EXACT Sciences in litigation relating to intellectual property rights; the possibility that other companies will develop and market novel or improved methods for detecting colorectal cancer; and the ability to raise additional capital on acceptable terms. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. EXACT Sciences undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional disclosure regarding these and other risks faced by EXACT Sciences, see the disclosure contained in EXACT Sciences' public filings with the Securities and Exchange Commission including, without limitation, its most recent Annual Report on Form 10-K and subsequent quarterly reports on Form 10-Q filed with the SEC.